Merus N.V. (MRUS)
| Market Cap | 732.97M |
| Revenue (ttm) | 45.63M |
| Net Income (ttm) | -63.64M |
| Shares Out | 46.30M |
| EPS (ttm) | -1.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 154,793 |
| Open | 16.10 |
| Previous Close | 16.07 |
| Day's Range | 15.72 - 16.23 |
| 52-Week Range | 12.03 - 30.81 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 36.92 (+133.23%) |
| Earnings Date | Feb 27, 2023 |
About MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145,... [Read more]
Financial Performance
In 2021, Merus's revenue was $49.11 million, an increase of 64.00% compared to the previous year's $29.94 million. Losses were -$66.82 million, -21.86% less than in 2020.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for MRUS stock is "Buy." The 12-month stock price forecast is $36.92, which is an increase of 133.23% from the latest price.
News
Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodie...
CORRECTING and REPLACING --Merus Provides 2023 Outlook
In a release issued January 8, 2023 by Merus N.V. (Nasdaq:MRUS) with the same headline, an error was made stating Merus plans to provide a regulatory path and program update on petosemtamab in the sec...
Merus Provides 2023 Outlook
- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy
Merus N.V. (MRUS) Reports Q3 Loss, Misses Revenue Estimates
Merus N.V. (MRUS) delivered earnings and revenue surprises of 11.67% and 38.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Merus Announces Financial Results for the Third Quarter and Provides Business Update
– Clinical update of MCLA-129 presented at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics – Zenocutuzumab (Zeno) Regulatory update: FDA recommends additional enro...
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
- MCLA-129 observed to be well tolerated with a favorable safety profile
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
– MCLA-129 observed to be well tolerated with preliminary evidence of anti-tumor activity during dose escalation phase
Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innov...
Merus to Participate in a Panel Discussion at Citi's 17th Annual BioPharma Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodi...
Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) delivered earnings and revenue surprises of 80% and 20.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Merus Announces Financial Results for the Second Quarter and Provides Business Update
- Clinical update of zenocutuzumab (Zeno) presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 05, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innova...
Does Merus N.V. (MRUS) Have the Potential to Rally 113% as Wall Street Analysts Expect?
The mean of analysts' price targets for Merus N.V. (MRUS) points to an 113.4% upside in the stock.
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodie...
Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- Robust 34% overall response rate and 9.1 months median duration of response across multiple NRG1+ tumor types
Down 32.1% in 4 Weeks, Here's Why Merus N.V. (MRUS) Looks Ripe for a Turnaround
Merus N.V. (MRUS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisin...
Merus N.V. (MRUS) Loses 30.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Merus N.V. (MRUS) as it is technically in oversold territory now.
Merus to Present at the H.C. Wainwright Global Investment Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies...
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) delivered earnings and revenue surprises of 34.85% and 36.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update
- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Company to host investor call on Sunday, June 5 at 6:00 p.m. ...
Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innov...
Merus Announces Publication in Nature Cancer on Petosemtamab's (MCLA-158) Unique Mechanism of Action
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innov...
Merus Presents Preclinical Data on MCLA-129 at the American Association for Cancer Research Annual Meeting 2022
– MCLA-129 promotes Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) of non-small cell lung cancer (NSCLC) cells– MCLA-129 significantly in...
Merus to Participate in a Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodi...